RTS, S/AS01 Malaria Vaccine Implementation in HighTransmission Sub-Saharan African Pediatric Populations: Efficacy and Challenges

Kato Jumba K.

Faculty of Science and Technology Kampala International University Uganda

                                                                                                 ABSTRACT
Malaria remains a leading cause of pediatric morbidity and mortality in sub-Saharan Africa, with Plasmodium falciparum accounting for over 90% of cases in high-transmission regions. The RTS, S/AS01 vaccine represents the first licensed malaria vaccine, targeting the circumsporozoite protein to prevent sporozoite invasion of hepatocytes. This review critically synthesizes evidence on RTS, S/AS01 implementation in high-transmission sub-Saharan African pediatric populations, focusing on molecular mechanisms, clinical efficacy, and programmatic challenges. A systematic literature search was conducted in PubMed, Embase, and Web of Science databases (2015–2024), selecting randomized controlled trials, implementation studies, immunological analyses, and systematic reviews. Phase III clinical trials demonstrated modest efficacy of 36% against clinical malaria and 32% against severe malaria in children aged 5–17 months following a four-dose regimen, with waning immunity requiring booster doses. Immunological studies reveal that RTS, S/AS01 induces anti-circumsporozoite antibodies and CD4+ T-cell responses, though protection is incomplete and variant-dependent. Pilot implementation programs in Ghana, Kenya, and Malawi have vaccinated over 2 million children, confirming feasibility and acceptable safety profiles, yet coverage gaps, logistical barriers, and interaction with seasonal malaria chemoprevention persist. Cost-effectiveness analyses support integration into existing vaccination schedules in high-burden settings, though long-term population-level impact requires ongoing surveillance. RTS, S/AS01 represents a significant advance in malaria control but requires complementary interventions and next-generation vaccine development to achieve elimination targets in endemic regions.

Keywords: RTS, S/AS01, Malaria vaccine, Circumsporozoite protein, Pediatric immunization, Sub-Saharan Africa.

CITE AS: Kato Jumba K. (2026). RTS, S/AS01 Malaria Vaccine Implementation in High-Transmission Sub-Saharan African Pediatric Populations: Efficacy and Challenges. Research Output Journal of Engineering and Scientific Research 5(1): 21-28.